The best thing medicine has handed us in a generation

Start with the good news, because it is genuinely good and the reflex of this trade is to bury it. For decades the advice offered to a person whose weight was quietly taking their knees, their sleep and their blood sugar amounted to try harder. Many of them did try harder, with more discipline than their critics have ever had to summon, and the biology handed it back. A class of medicine that interrupts that loop is one of the few unambiguous wins medicine has delivered to ordinary people in a generation, and it belongs on the same shelf as statins and vaccines rather than in the vanity aisle.

It is worth being precise about what changed, because the precision is the argument. In the pivotal trial of semaglutide, 1,961 adults with obesity lost a mean 14.9 percent of body weight over 68 weeks; tirzepatide at its highest dose took a mean 22.5 percent off over 72 weeks. Those are not diet-book numbers, they are surgical numbers arriving in a pen. The drugs did not supply willpower. They lowered the price of using it. The person who could never get past the fourth week now gets past it, and everything that was true about diet and training before is suddenly true for them too — reachable rather than theoretical. That is what a good treatment does: it moves the hard thing into range.

So the honest criticism is not that the medicine is a shortcut. It is that we have finished the exciting half of a system at extraordinary speed and left the boring half unbuilt. The dispensing side is a real feat of engineering — a form, a supply chain, a subscription, a cold chain, a pen in a box on a Tuesday, at a $499 self-pay list price a month. The other side needs protein and fiber a person can actually cook, resistance training so that what leaves is fat rather than the muscle they will want at seventy, a clinician who catches nausea before it becomes dehydration, and a plain conversation about what happens when they stop.

That last item is the load-bearing one, and it is the one nobody sells. The trial that produced the 14.9 percent also followed people after withdrawal, and body weight climbed back toward baseline within a year, taking the cardiometabolic gains with it. Remove an appetite treatment and appetite returns; that is not a betrayal, it is the mechanism behaving exactly as described. But it means a person is entitled to know at the first appointment whether they are buying a course or a subscription, and to be given the option of building something underneath the drug that can hold when the drug comes off.

None of this is an argument for rationing, for scolding, or for the tedious insistence that people should have simply eaten less. That argument has been run for forty years and lost. It is an argument that the cheap half of this is now the missing half — a barbell, a protein target, a calendar with follow-up dates on it, and a taper written down before it is needed. Set against $499 a month, that is rounding error.

The plate on this piece is drawn the way it works when it is done properly, because that is the case we are making: the pen at the front, the door open behind it, and the room past the door with people in it. We drew the bricked-up version too, and kept it — it is the gap, honestly reported. It is not the verdict.

The optimistic reading is the correct one. We have the hard part. The part still outstanding is a corridor, a calendar and a rack of weights, which is to say the part we are actually good at. It would be a strange kind of pessimism to solve the biology and then decide the joinery is beyond us.